Newsroom - Page 3

Health plans and pharmacy benefits managers are expected to scrutinize the FDA approval to ensure that only those patients who truly need the drug get it.Drugmakers say discounts will cause the price to fall below the $14,600 annual wholesale price listed.
At the ongoing annual ACS NSQIP Conference in Chicago, physicians from the Thomas Jefferson University Hospital in Philadelphia presented a risk score tool that can predict a person's dependence on mechanical ventilation post surgery.
The HHS Secretary told the National Governors Association that she needed their help in fighting substance abuse and in moving the healthcare system from a volume-based to a value-based system.
There is a link between low-value prescribing and graduate medical training, according to a study led by researchers at the Perelman School of Medicine at the University of Pennsylvania and published in the Journal of General Internal Medicine.
The high cost of running a state-based health insurance exchanges created under the Affordable Care Act could lead to states turning over operations to the federal government or joining forces with other states.
This week Bristol-Myers Squibb's phase 3 nivolumab study ended early because renal cell carcinoma patients were experiencing significantly better overall survival, the American Society of Clinical Oncology called for the inclusion of more geriatric patients in trials, and Medicaid expansion states are finding more people enrolling than they planned.
The Sanofi and Regeneron therapy, to be marketed as Praluent, was among the most-anticipated FDA approvals of the year. Late-day reports put pricing at $40 a day wholesale, well above estimates, although insurers will seek discounts.
The FDA approved Daklinza (daclatasvir) for use with sofosbuvir to treat hepatitis C virus genotype 3 infections.